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Aims The metabolic syndrome (MS) is associated with an increased cardiovascular risk. Patients with the MS have endo-
thelial dysfunction, decreased circulating adiponectin, and a high expression of angiogenic inhibitors such as plasmi-
nogen activator inhibitor-1 (PAI-1). We hypothesized that such patients, in the event of a coronary occlusion, might
exhibit a less developed collateral circulation.
Methods
and results
Three hundred and eighty-seven consecutive patients with at least one coronary occlusion of a major coronary vessel
at diagnostic angiography were prospectively enrolled. Collateral development was graded with validated angio-
graphic methods. The MS was deﬁned according to the ATP-III deﬁnition. Fasting glucose, adiponectin, insulin con-
centrations, and PAI-1 were measured at the time of angiography. MS was associated with less developed collateral
vessels (P ¼ 0.005). In multivariable analysis adjusting for potential confounding factors including the duration of
coronary occlusion (P ¼ 0.0001), fasting glycaemia (P ¼ 0.0007), low adiponectin concentration (P ¼ 0.01), insulin-
resistance (HOMA-IR; P ¼ 0.01), high circulating PAI-1 concentration (P ¼ 0.01), and hypertension (P ¼ 0.008)
were independently associated with poor coronary collateral vessel development.
Conclusion This study shows that in patients with coronary occlusion, collateral circulation is impaired in patients with the MS.
This association is partly related to fasting glycaemia and to key parameters linked to insulin resistance.
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The metabolic syndrome (MS) is a cluster of risk factors such
aselevatedbloodpressure,dyslipidaemia,andcentralobesity,associ-
ated with various biological manifestations, including hyperglycaemia
andinsulinresistance.
1PatientswiththeMShaveanincreasedriskfor
cardiovascular morbidity and mortality.
2
Development of coronary collateral circulation is an important
adaptive mechanism occurring in patients with occlusive coronary
artery disease. Well-developed coronary collaterals reduce the
size of myocardial infarction, preserve left ventricular function
and viability, and reduce the risk of death.
3 Patients with the MS
have endothelial dysfunction,
4 decreased circulating adiponectin,
and heightened expression of plasminogen activator inhibitor-1
(PAI-1), which may negatively inﬂuence vessels remodelling and
growth.
5,6 However, whether these patients have a maladaptive
response to coronary occlusion, manifested as a less developed
collateral circulation, remains a matter of debate. Indeed, in a
recent study, patients with hypertension, but not patients with
the MS had less developed coronary collaterals.
7,8 However, in
the studied population, only 24 patients had occluded coronary
vessels and no information on the duration was available.
7
As the growth of collaterals is a time-dependent process,
9
occurring only in case of severe ischaemia secondary to tight ste-
noses or occluded vessels,
10 we investigated the inﬂuence of the
MS on collateral circulation in a population that comprised only
patients with occluded coronary vessels, and after adjustment on
the time elapsed since coronary occlusion. In addition, we investi-
gated the potential relationship between biological variables
related to the MS, such as PAI-1 and adiponectin plasma concen-
tration, and the development of coronary collateral circulation.
Because circulating endothelial progenitor cells (EPCs), including
‘early EPCs’, have been demonstrated to play a signiﬁcant role in
the growth of new vessels, we further investigated the potential
relationship between the presence of the MS and the number of
circulating ‘early EPCs’.
Methods
Study population
Between May 2000 and October 2001, 2050 patients scheduled for
coronary angiography were prospectively enrolled in a cardiovascular
registry. The Ethics Committee of the ‘Centre Hospitalier Re ´gional
Universitaire de Lille’ approved the study and each subject gave
informed written consent the day before angiography. Patients who
required unplanned coronary angiography (e.g. patients addressed
for emergent angiography or for primary or rescue PCI) were not
part of this registry.
We prospectively selected all patients who had at least one total
occlusion of a major coronary vessel excluding only patients with a
history of coronary artery bypass graft. Three hundred and eighty-
seven patients fulﬁlled these criteria and made up the study population.
The baseline clinical and angiographic characteristics as well as cardio-
vascular medications were prospectively recorded by trained cardiolo-
gists at the time of enrolment.
Patients were fasting and hypoglycaemic drugs were stopped for at
least 12 h before angiography. Blood samples were drawn from the
arterial sheath immediately after puncture for angiography. Insulin was
measured with an immunometric assay. PAI-1 and adiponectin were
measured by ELISA according to the manufacturer’s directions. In
order to evaluate the potential relationship between the number of
circulating ‘early EPCs’ and the presence of the MS, 30 consecutive
patients underwent blood sampling to evaluate colony forming unit
endothelial cells (CFU-ECs) from peripheral mononuclear cells.
Deﬁnitions
MS was deﬁned according to the ATP-III criteria, including three or
more of the following abnormalities including high blood pressure
( 130/85 mmHg or the use of antihypertensive drugs) and metabolic
derangements such as hypertriglyceridemia [serum triglycerides
 1.70 mmol/L (150 mg/dL)],lowHDLcholesterol[serum HDLcholes-
terol ,1.04 mmol/L (40 mg/dL) in men and ,1.29 mmol/L (50 mg/dL)
in women], high fasting glucose [fasting serum glucose  6.1 mmol/L
(110 mg/dL)], and obesity. As waist circumference was not available,
obesitywasdeﬁnedasabodymassindex .30 kg/m
2.
1Diabetesmellitus
was deﬁned as a fasting glucose  7 mmol/L on two separate occasions,
theuseofhypoglycaemicagents,orahistoryofphysician-diagnoseddia-
betes mellitus. The homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated by the following formula: HOMA-IR¼
(fasting glucose   fasting insulin)/22.5.
11
Angiography procedure and coronary
collaterals grading
Selective coronary angiography was performed in multiple orthogonal
projections by experienced investigators using a standardized pro-
cedure including: 6 Fr catheters (Cordis), administration of intracoron-
ary nitrates, standardized contrast media (iohexol350), and injection
method. All angiograms were recorded at 35 frames/s and stored on a
high qualitysupport. Ventricularfunction wasevaluated in a single-plane
right anterioroblique projection(308), and left ventricularejection frac-
tion (LVEF) was calculated according to the area length method.
Two independent observers, blinded to patient characteristics,
graded the severity of coronary artery disease and evaluated the col-
lateral ﬂow. These evaluations were used for the calculation of the
inter-observer variability. In the case of disagreement, a new reading
involving the two observers acting as a panel was performed and the
resulting agreement was accepted as the ﬁnal grading (see Supplemen-
tary material online, data 1 for details).
12 Values of kappa weighted for
multiple categories (wk) were computed to calculate the agreement
between observers in grading ‘collateral ﬂow grade’ and ‘recipient
ﬁlling grade’.
13 Agreement between the two observers in grading the
‘recipient ﬁlling grade’ (wk ¼ 0.739) or the ‘collateral ﬂow grade’
(wk ¼ 0.867) was very good.
Variability of the measurement overtime was analysed in 21 patients
in whom the following conditions were met: (i) no revascularization
was performed after the initial angiography and (ii) a repeated angio-
graphy was performed within 10 days. Agreement between the two
sets of angiography in grading the ‘Recipient ﬂow grade’ (wk ¼
0.844) or the ‘collateral ﬂow grade’ (wk ¼ 0.874) was very good.
Time elapsed since coronary occlusion
For each patient, the time elapsed since coronary occlusion was eval-
uated based on a review of clinical data and after review of all available
ECGs. This was performed by a physician who was not involved in
grading coronary collateral ﬂow. Patients were classiﬁed into ﬁve
groups based on the estimated duration of coronary occlusion: (1)
,15 days; (2) 15 days to 1 month; (3) 1–6 months; (4) .6 months,
and (5) unknown but no evidence of an event during the month pre-
ceding angiography. In patients in whom the duration of coronary
MS and collateral vessel formation in patients with documented occluded coronary arteries 841occlusion was ,15 days, the median time between symptoms and
angiography was 5 (3–9) days.
Isolation, culture and phenotyping of colony
forming unit endothelial cells
There are at least two morphological and functionally distinct EPC
populations among circulating mononuclear cells involved in the angio-
genic process.
14 The early spindle-like outgrowth cells (‘early EPCs’)
possess a relatively low proliferative capacity and are considered to
act partly indirectly through the production of high levels of angiogenic
cytokines. Late ‘outgrowth cells’ show a high proliferative potential and
are considered as circulating angioblasts. In the present study, the
relation between MS and EPCs has been assessed by investigating
‘early EPCs’.
Isolation and culture of ‘early EPCs’ (CFU-ECs) were performed
according to previously described methods (see Supplementary
material online, data 2 for details).
15,16 Demonstration of VEGF
secretion was performed by the measurement of VEGF concentration
of supernatant (478+154 pg/10
6 cells) as previously described.
17
Statistical analysis
Continuous variables are presented as mean+SD [or median (inter-
quartile range) when data were skewed]. Discrete variables are pre-
sented as absolute number and percentages. Comparison between
patients with/without the MS was performed using Students’ t-test
(the Mann–Whitney rank-sum test for skewed variables) or the x
2
analysis when appropriate. Relationships between the ‘collateral ﬂow
grade’ or ‘recipient ﬁlling grade’ and continuous variables were
assessed using Spearman’s correlation coefﬁcient, whereas relation-
ships with discrete variables were assessed using the Mantel–Haenszel
linear tendency test.
Multivariable analyses were performed with a general linear model.
ToassesstheassociationbetweencollateralﬂowgradeandLVEF,amul-
tivariable analysis was performed adjusting on age, sex, smoking, dia-
betes mellitus, total cholesterol, clinical symptoms, number of vessels
with total occlusion, collateral ﬂow grade, time since coronary occlu-
sion, and cardiovascular medications. To evaluate the relation
between‘collateral ﬂowgrade’and thedemographicand clinical charac-
teristics of the subjects, the multivariable model included age, sex,
smoking, total cholesterol, time since coronary occlusion, clinical symp-
toms, use of ACE-inhibitors, the use of statins and the number of dis-
eased coronary vessels. These variables were selected on the basis of
previouspublicationsondevelopment ofcollateralcirculationinexperi-
mental and clinical settings
18–22 and on variables associated with
‘collateral ﬂow grade’ at P , 0.1 in the present study. The same adjust-
ment variables were used to assessthe relation between ‘collateral ﬂow
grade’ and MS or its components separately (high blood pressure,
hypertriglyceridaemia, low HDL cholesterol, high fasting glucose,
obesity, HOMA-IR, PAI-1, and adiponectin concentration) in additional
multivariable analyses. Similar analyses were performed with ‘recipient
ﬁlling grade’. All hypotheses were two-tailed with a 0.05 type I error.
Results
Baseline characteristics according to the
presence of the metabolic syndrome
The baseline characteristics of the subjects are presented Table 1.
One hundred and eighty-one patients (47%) met the criteria for
the MS. Patients with the MS were more likely to be women
(P ¼ 0.01) and diabetic (P ¼ 0.0004). Total cholesterol (P ¼
0.01), insulin (P ¼ 0.0001), HOMA-IR (P ¼ 0.0001), HbA1c (P ¼
0.0001), and PAI-1 (P ¼ 0.0008) levels were higher and adiponectin
(P ¼ 0.0002) concentration was lower in patients with the MS. The
differences observed between subjects with or without the MS
remained statistically signiﬁcant after exclusion of diabetic patients
(data not shown). Patient with the MS had also more severe cor-
onary artery disease (P ¼ 0.02) and less developed collateral circu-
lation as estimated by the ‘recipient ﬁlling grade’ or the ‘collateral
ﬂow grade’ (P ¼ 0.005).
Coronary collateral circulation evaluated
by angiography and relation with left
ventricular ejection fraction
The two grading scores were highly correlated to each other
(R¼0.76, P ¼ 0.0001). A signiﬁcant and positive correlation was
observed between LVEF and the ‘collateral ﬂow grade’ (P ¼
0.005, Table 2) or the ‘recipient ﬁlling grade’ (P ¼ 0.01). In multi-
variable analyses adjusting for age, gender, smoking, diabetes,
total cholesterol, clinical symptoms, number of vessels with total
occlusion, time since coronary occlusion, and cardiovascular
medications, the coronary collateral circulation estimated by the
‘collateral ﬂow grade’ (P ¼ 0.005) or by the ‘recipient ﬁlling
grade’ (P ¼ 0.01) was highly associated with LVEF.
Analysis of the association between
metabolic syndrome and coronary
collateral circulation
As analyses of the relation between ‘collateral ﬂow grade’ and
‘recipient ﬁlling grade’ yielded similar results, only those relative
to ‘collateral ﬂow grade’ are presented.
Coronary collateral circulation was signiﬁcantly less developed in
patients with diabetes (P ¼ 0.005) and raised LDL cholesterol levels
(P ¼ 0.04), whereas it was more developed in patients with an old
occlusions (P ¼ 0.0001) and more diffuse coronary artery disease
(P ¼ 0.01, Table 2). The association between collateral ﬂow grade
and clinical variables (age, sex, smoking, total cholesterol, time
since coronary occlusion, clinical symptoms, use of ACE-inhibitors,
use of statins, and number of diseased coronary vessels) was tested
in a multivariable analysis. In this model, a shorter time since coron-
ary occlusion (b ¼þ0.297; P ¼ 0.0001), female sex (b ¼20.483;
P ¼ 0.003), and smoking (b ¼20.446; P ¼ 0.003) were associated
with a signiﬁcantly lower grade of collateral ﬂow (Figure 1).
In univariable analyses, MS was associated with a lower
grade of collateral ﬂow (P ¼ 0.005, Table 3). The collateral ﬂow
grade was inversely correlated to the number of components of
the MS (P ¼ 0.002), high blood pressure (P ¼ 0.04), fasting glycae-
mia .6.1 mmol/L (P ¼ 0.002), insulin concentration (P ¼ 0.04),
HOMA-IR (P ¼ 0.03), and PAI-1 concentration (P ¼ 0.02) and
positively correlated to adiponectin concentration (P ¼ 0.001). In
order to further assess the relationship between coronary collat-
eral ﬂow grade and the MS, multivariable analyses were performed
(Table 4). First, the association between the MS and collateral ﬂow
grade was assessed by using the MS as a quantitative data (from 0
to 5 according to the number of components of the MS) in a
model adjusted for potential confounding factors (age, sex,
smoking, total cholesterol, time since coronary occlusion, clinical
F. Mouquet et al. 842symptoms, use of ACE-inhibitors, use of statins, and number of dis-
eased coronary vessels). In this model, the MS was associated with
a lower collateral ﬂow grade (P ¼ 0.0003, Model 1; Table 4,
Figure 2). Similar results were observed when the MS was
entered as a qualitative data (yes vs. no, b ¼2381; P ¼ 0.001)
adjusted for the same confounding factors. Finally, as an alternative
to MS, the relation between individual components of the MS (high
blood pressure, hypertriglyceridaemia, low HDL cholesterol, high
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Table 1 Demography, biology, and angiography with respect to the presence of the metabolic syndrome
Controls (n 5 206) Metabolic syndrome (n 5 181) P-value
Age (years) 62+12 63+11 0.71
Female sex, n (%) 29 (14) 43(24) 0.01
Risk factors, n (%)
Smoking 164 (79) 130 (72) 0.20
Diabetes mellitus 42 (24) 93 (44) 0.0001
Familial history of CAD 67 (33) 68 (38) 0.33
Total cholesterol (mg/dL) 177 (150–203) 193 (155–217) 0.01
LDL cholesterol (mg/dL) 115 (89–138) 118 (93–144) 0.28
Biological variables related to the metabolic syndrome
Insulin (mUI/L) 5.9 (4.0–8.7) 8.9 (5.8–13.4) 0.0001
HOMA-IR 1.45 (0.90–2.32) 2.59 (1.52–4.56) 0.0001
HbA1C (%) 5.5 (5.2–5.9) 6.4 (5.6–8.1) 0.0001
C-reactive protein (mg/L) 3.50 (1.76–11.30) 6.04 (2.11–12.32) 0.12
Fibrinogen (g/L) 3.82 (3.17–4.67) 4.11 (3.36–4.81) 0.10
PAI-1 (ng/mL) 22 (15–32) 25 (19–35) 0.0008
Adiponectin (ng/mL) 7982 (4176–12424) 5567 (3213–9110) 0.0002
Cardiovascular medications, n (%)
Oral antiplatelet 183 (89) 149 (84) 0.18
ACE-inhibitors 112 (54) 103 (58) 0.56
Beta-blockers 126 (61) 116 (65) 0.48
Nitrates 122 (59) 107 (60) 0.94
Calcium antagonists 49 (24) 45 (25) 0.82
Statins 116 (56) 109 (61) 0.35
Clinical symptoms, n (%)
Stable symptoms 125 (61) 101 (56) 0.47
Unstable symptoms 81 (39) 80 (44)
Angiographic data
Number of vessels with 50% stenosis, n (%)
One vessel 66 (32) 44 (24) 0.02
Two vessels 77 (37) 62 (34)
Three vessels 63(31) 75 (42)
Number of vessels with total occlusion, n (%)
One vessel 180 (87) 142 (79) 0.02
Two vessel 26 (13) 39 (21)
Time since coronary occlusion, n (%)
,15 days 54 (26) 39 (22) 0.61
15 days to 1month 10 (5) 13 (7)
1–6 months 26 (13) 22 (12)
Unknown .1 month 47 (23) 42 (23)
.6 months 69 (33) 65 (36)
LVEF (%) 52.5+15.0 49.4+15.4 0.15
Collateral ﬂow grade 2.84+1.04 2.22+1.19 0.005
Recipient ﬁlling grade 3.15+1.00 2.63+1.20 0.005
Data are presented as percent of patients, mean value+SD or median (inter-quartile range). CAD, coronary artery disease; BMI, body mass index.
MS and collateral vessel formation in patients with documented occluded coronary arteries 843fasting glucose, obesity, HOMA-IR, adiponectin, and PAI-1), and
collateral ﬂow grade was assessed. High fasting glycaemia (P ¼
0.0007), high blood pressure (P ¼ 0.008), HOMA-IR (P ¼ 0.01),
adiponectin (P ¼ 0.01), and PAI-1 (P ¼ 0.01) were signiﬁcantly
associated with collateral ﬂow grade (Model 2, Table 4). Similar
associations were observed when analyses were restricted to
patients with only one coronary occlusion (data not shown).
Metabolic syndrome and endothelial
progenitor cells
Median CFU-ECs, as measured in 30 consecutive patients, was
12.2 (3.0–29.0) colonies/mL. Median CFU-ECs was lower in
smokers [5.2 (1.0–21.7), n ¼ 21] than in non-smokers [27.0
(20.5–72.5), n ¼ 9; P ¼ 0.004]. It was also lower in patients
with the MS [3.0 (0.6–12.8), n ¼ 12] than in those without [25.5
(4.9–53.3), n ¼ 18; P ¼ 0.01]. Interestingly, the number of
CFU-ECs was inversely related to the number of components
of the MS present (r ¼ 0.59, P ¼ 0.005; Fig. 2B). Among the
individual components of the MS, the strongest inverse relationship
was found with fasting glycaemia .6.1 mmol/L (P ¼ 0.01) and
high blood pressure (P ¼ 0.05). Among the other biological
parameters related to the MS, a signiﬁcant and inverse relationship
was found with adiponectin concentration (r ¼ 20.51, P ¼ 0.005)
and HOMA-IR (r ¼ 20.36, P ¼ 0.05). No signiﬁcant relationship
was found with PAI-1 concentration or cardiovascular medications.
Discussion
To our knowledge, this study is the ﬁrst to demonstrate a strong
and inverse relationship between the presence of the MS and
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Table 2 Demography, biology, and angiography with respect to the coronary collateral circulation
Collateral ﬂow grade 0 (n 5 23) 1 (n 5 45) 2 (n 5 102) 3 (n 5 140) 4 (n 5 77) P-value
Age (years) 65+10 59+13 63+11 61+11 65+12 0.42
Female sex, n (%) 5 (21) 10 (22) 24 (24) 24 (17) 12 (9) 0.08
Risk factors, n (%)
Smoking 20 (87) 35 (78) 76 (74) 107 (76) 56 (73) 0.19
Diabetes mellitus 13 (56) 18 (40) 42 (41) 38 (27) 24 (31) 0.005
Familial history of CAD 4 (17) 21 (46) 29 (28) 47 (34) 34 (44) 0.14
Total cholesterol (mg/dL) 184 (158–216) 199 (169–225) 187 (160–211) 182 (145–206) 174 (144–216) 0.08
LDL cholesterol (mg/dL) 126 (107–137) 125 (105–146) 118 (93–140) 111 (89–140) 111 (84–147) 0.04
Cardiovascular medications, n (%)
Oral antiplatelet 21 (91) 37 (82) 89 (87) 120 (86) 65 (84) 0.68
ACE-inhibitors 13 (57) 23 (51) 66 (65) 72 (51) 41 (53) 0.47
Beta-blockers 17 (74) 25 (56) 65 (64) 85 (61) 50 (65) 0.92
Nitrates 19 (83) 31 (69) 56 (55) 72 (51) 51 (66) 0.26
Calcium antagonists 3 (13) 10 (22) 25 (25) 34 (24) 22 (29) 0.28
Statins 13 (57) 26 (58) 55 (54) 83 (59) 48 (62) 0.40
Clinical symptoms, n (%)
Stable symptoms 9 (39) 14 (31) 55 (54) 94 (67) 54 (70) 0.0001
Unstable symptoms 14 (61) 31 (69) 47 (46) 46 (33) 23 (30)
Time since coronary occlusion, n (%)
,15 days 14 (61) 22 (49) 32 (31) 16 (11) 9 (12) 0.0001
15 days to 1 month 2 (9) 1 (2) 10 (10) 8 (6) 2 (3)
1–6 months 4 (17) 3 (7) 13 (13) 21 (15) 7 (9)
Unknown .1 month 1 (4) 9 (20) 19 (19) 42 (30) 18 (23)
.6 months 2 (9) 10 (22) 28 (27) 53 (38) 41 (53)
Angiographic data
Number of vessels with 50% stenosis, n (%)
One vessel 7 (31) 13 (29) 40 (39) 37 (26) 13 (17) 0.01
Two vessels 10 (43) 16 (35) 36 (35) 54 (39) 23 (30)
Three vessels 6 (26) 16 (36) 26 (26) 49 (35) 41 (53)
Number of vessels with total occlusion, n (%)
One vessel 22 (96) 41 (91) 90 (88) 112 (80) 57 (74) 0.04
Two vessels 1 (4) 4 (9) 12 (12) 28 (20) 20 (26)
LVEF (%) 46.9+13.3 48.9+13.9 51.5+11.4 52.0+16.6 53.0+16.0 0.005
F. Mouquet et al. 844the extent of the development of the collateral circulation in
patients. It also demonstrates that hyperglycaemia, insulin resist-
ance (HOMA-IR), hypertension, circulating PAI-1, and adiponectin
concentration are independently associated with poor coronary
collateral vessel development. These ﬁndings could partly
account for the poor clinical outcome reported in patients with
coronary artery disease who have the MS.
2
Factors associated with the development
of ‘chronic’ coronary collateral
circulation and the need for adjustment
for these factors
Previous studies have clearly demonstrated that myocardial ischae-
mia related to tight stenoses or occluded coronary vessels plays a
major role in the development of coronary collaterals.
10 In the
present study, performed in patients with occluded coronary
vessels, the time elapsed since occurrence of coronary occlusion
is the most powerful correlate of well developed coronary collat-
eral vessels, in agreement with earlier hypotheses.
9 Therefore, the
importance of the ischaemic stimuli and a sufﬁcient time are
necessary to develop collateral circulation. Furthermore, these
results clearly shows that these factors should be taken into
account when analysing other correlates of coronary collateral
vessel development.
Interestingly, our study also identiﬁes, to our knowledge for the
ﬁrst time, smoking and female sex as independent correlates of
poor coronary collateral circulation. The poor coronary collateral
circulation observed in smokers is consistent with studies in
animals demonstrating that exposure to cigarette smoke impairs
angiogenesis in response to ischaemia by inhibiting VEGF through
a decreased expression of HIF-1alpha.
19 Our observation as well
Figure 1 Female sex (P ¼ 0.003) and smoking (P ¼ 0.003) are
associated with a lower ‘collateral ﬂow grade’.
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Table 3 Relationship between components of the metabolic syndrome as well as related biological variables with the
extent of coronary collateral circulation
Collateral ﬂow grade 0 (n 5 23) 1 (n 5 45) 2 (n 5 102) 3 (n 5 140) 4 (n 5 77) P-value
Metabolic syndrome
No 8 (35) 18 (42) 57 (56) 77 (55) 46 (60) 0.005
Yes 15 (65) 27 (58) 45 (44) 63 (45) 31 (40)
Number of components of MS
0–1 2 (9) 10 (22) 23 (23) 34 (24) 23 (30)
2–3 10 (43) 21 (47) 56 (55) 84 (60) 40 (52) 0.002
4–5 11 (48) 14 (31) 23 (22) 22 (16) 14 (18)
Components of the metabolic
syndrome
Obesity (BMI . 30 kg/m
2) 12 (52) 18 (42) 23 (23) 39 (28) 23 (30) 0.06
High blood pressure 17 (74) 24 (53) 62 (61) 68 (48) 39 (50) 0.04
Low HDL cholesterol 19 (83) 32 (71) 75 (73) 111 (79) 54 (70) 0.41
High triglycerides 6 (27) 45 (49) 41 (40) 57 (41) 26 (34) 0.33
Fasting glycaemia .6.1 mmol/L 18 (78) 24 (56) 49 (48) 55 (39) 33 (43) 0.002
Other biological variables
Insulin (mUI/L) 9.60 (6.80–16.10) 8.90 (6.90–12.60) 6.70 (4.80–10.70) 6.60 (4.50–11.70 6.50 (4.50–10.00 0.04
HOMA-IR 3.15 (1.97–4.41) 2.53 (1.78–4.74) 1.93 (1.01–3.14) 1.61 (1.10–3.10) 1.70 (1.08–2.71) 0.03
HbA1C (%) 6.1 (5.4–6.6) 5.8 (5.3–7.1) 5.8 (5.3–7.2) 5.6 (5.3–6.5) 5.8 (5.3–6.6) 0.37
C-reactive protein (mg/L) 6.99 (1.00–11.90) 6.75 (1.88–13.12) 6.23 (2.31–16.62) 3.44 (1.71–8.20) 3.44 (2.10–14.65) 0.16
Fibrinogen (g/L) 3.96 (2.69–4.51) 4.09 (3.30–5.20) 4.22 (3.36–4.81) 3.81 (3.14–4.74) 4.03 (3.37–4.77) 0.45
Adiponectin (ng/mL) 5170 (2462–8057) 5480 (3385–8358) 6648 (3421–10834) 6807 (3674–11533) 7529 (3664–12269) 0.001
PAI-1 (ng/mL) 33 (19–44) 27 (18–40) 23 (17–35) 22 (16–34) 21 (16–33) 0.01
MS, metabolic syndrome; BMI, body mass index. Trends were tested using Spearman’s correlations and Mantel–Haenszel linear tendency tests.
MS and collateral vessel formation in patients with documented occluded coronary arteries 845as that of others
16 that smokers have less circulating ‘early EPCs’
also suggest an important role of this mechanism.
The poor coronary collateral circulation observed in women
may be related to the fact that 96% of the female population
was older than 50 years and therefore post-menopausal. Evidence
suggests that oestrogen directly modulates angiogenesis via effects
on endothelial cells under physiological and pathophysiological
conditions and that its loss in post-menopausal women is associ-
ated with a decreased angiogenic response.
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Consideration of the results from
previous studies investigating the impact
of diabetes and components of the
metabolic syndrome on coronary
collateral circulation
Wefoundaclearandinverseassociation betweentheextentofcol-
lateral formation and the presence of diabetes mellitus, the MS, or
markers of insulin resistance. The results of earlier studies have
beenconﬂicting;somesuggestedthatdiabeteshadnoimpactoncol-
lateral development,
23,24 others that diabetes was associated with
decreased collaterals,
25–27 and one reported that diabetes was
associated with increased collateral development
28 (see Sup-
plementary material online, Table S3 for details). Recently, a group
reported that patients with hypertension, but not patients with
the MS, had less developed coronary collaterals.
7,8
With respect to hypertension, our study conﬁrms that it is
associated with less coronary collaterals in ischaemic myocar-
dium.
8 The effect of hypertension could be related partly to a det-
rimental effect on the number of ‘early EPCs’, as suggested by our
results, and on the migratory properties of EPCs.
16 It could also be
related to a profound downregulation of an important endothelial
growth factor, hepatocyte growth factor, as demonstrated in
spontaneous-hypertensive rats.
The apparent discrepancies regarding the relationship between
diabetes/MS and collateral circulation may be related to: (i) differ-
ences in the severity of CAD among the populations studied; (ii)
the lack of adjustment for major known confounding factors; and
(iii) the small sample size of most of these studies (see Supplemen-
tary material online, Table S3 for details). Indeed, most studies,
including the most recent,
7 enrolled a broad range of patients
with coronary artery disease where only a minority of patients
had severely stenosed or occluded coronary vessels.
25,28,29 Fur-
thermore, apart from a small study that included 90 patients,
27
the analyses were not adjusted to account for the time elapsed
since coronary occlusion,
24,26 and confounders such as sex or
smoking were not taken into account.
We sought to avoid these pitfalls by studying a relatively large
population of 387 patients, exclusively including individuals with
occluded coronary vessels and adjusting for major confounding
factors such as time elapsed since coronary occlusion, smoking,
and sex.
................................................. .................................................
...............................................................................................................................................................................
Table 4 Association between metabolic syndrome and ‘collateral ﬂow grade’: multivariable analyses
Model 1 Model 2
b 95% CI P-value b 95% CI P-value
Time since coronary occlusion þ0.299 þ0.219 to þ0.365 0.0001 þ0.281 þ0.187 to þ0.372 0.0001
Female sex 20.402 20.790 to 20.090 0.01 20.351 20.739 to 20.071 0.03
Smoking 20.443 20.784 to 20.188 0.002 20.447 20.789 to 20.179 0.003
Age (10 years increase) 20.043 20.155 to þ0.070 0.46 20.039 20.154 to 20.075 0.49
Total cholesterol (10 mg/dL increase) þ0.006 20.018 to þ0.030 0.64 þ0.008 20.015 to þ0.031 0.51
Number of diseased coronary vessels þ0.084 20.067 to þ0.235 0.27 þ0.057 20.095 to þ0.210 0.46
Unstable symptoms 20.020 20.298 to þ0.258 0.89 20.059 20.340 to þ0.222 0.67
Use of ACE-inhibitors þ0.001 20.210 to þ210 0.99 þ0.009 20.197 to þ228 0.89
Use of statins 20.008 20.223 to þ207 0.94 20.002 20.219 to þ215 0.99
Number of components of the metabolic syndrome (0–5) 20.148 20.229 to 20.075 0.0003 — — —
Fasting glycaemia . 6.1 mmol/L — — — 20.397 20.639 to 20.160 0.0007
High blood pressure — — — 20.283 20.508 to 20.078 0.008
PAI-1 (10 ng/mL increase) — — — 20.030 20.069 to 20.009 0.01
HOMA-IR (1 U increase) — — — 20.031 20.058 to 20.008 0.01
Adiponectin (10
3mg/mL increase) — — — þ0.027 þ0.005 to þ0.051 0.01
High Triglycerides — — — 20.028 20.273 to þ0.216 0.81
Low HDL cholesterol — — — þ0.043 20.216 to þ0.303 0.74
Obesity — — — 20.136 20.377 to þ0.104 0.26
Model 1 included age, sex, smoking, total cholesterol, time since coronary occlusion, clinical symptoms, use of ACE inhibitors, use of statins, number of diseased coronary vessels
and the number of components of the metabolic syndrome(0 to 5).
Model 2 included age, sex, smoking, total cholesterol, time since coronary occlusion, clinical symptoms, use of ACE inhibitors, use of statins, and number of diseased coronary
vessel, plus high blood pressure, hypertriglyceridemia, low HDL cholesterol, high fasting glucose, obesity, HOMA-IR, adiponectin and PAI-1 concentration.
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coronary collateral development:
biological associations
Our study demonstrates that in patients with coronary occlusion,
those with the MS have less developed coronary collateral vessels.
In addition, it appears that the extent of collateral vessel develop-
ment and the number of circulating ‘early EPCs’ are inversely
related to the number of components of the MS present. Further-
more, multivariable analysis including clinical and biological vari-
ables suggest that hyperglycaemia, insulin resistance (HOMA-IR),
hypertension, low adiponectin concentration, and high PAI-1 con-
centration in blood are independently associated with poor coron-
ary collateral vessel development.
A potential role for hyperglycaemia has been previously
suggested, based on studies in animals with chronic hyperglycae-
mia.
30 This could partly reﬂect a decreased expression of VEGF
in the myocardium, a decreased sensitivity to VEGF stimulation,
31
or a direct inhibitory effect of hyperglycaemia on ‘early EPCs’ as
suggested by our results and by previous in vitro studies.
32
The reported effect of insulin resistance on collateral circulation
and ‘early EPCs’ number is also supported by the results of studies
in animal.
33 They demonstrate that insulin is an important regulator
of the angiogenic pathway and that rat models of insulin resistance
are associated with a decreased expression of both VEGF and Akt
leading to a decreased vascular density in myocardium in response
to ischaemia.
33
Adiponectin is an adipocyte-derived cytokine downregulated in
patients with MS and known to have angiogenic properties in
animals.
34 By demonstrating that a high adiponectin plasma level
is independently associated with a good coronary collateral circu-
lation, our results conﬁrm these observations in the clinical situ-
ation. Adiponectin is considered to promote angiogenesis by
promoting endothelial cell proliferation and migration and by sup-
pressing apoptosis.
34 Interestingly, our results also suggest a role of
adiponectin on circulating ‘early EPCs’. This supports the previous
observation that adiponectin stimulate proliferation of human
EPCs
35 in vitro.
A high concentration of PAI-1 in blood is one of the features of
the MS.
4 Our study is the ﬁrst to our knowledge to demonstrate a
negative relationship between plasma PAI-1 concentration and the
development of collateral circulation in humans. Our observation
extends previous reports demonstrating that decreasing PAI-1
expression in animals stimulate vessel growth in response to myo-
cardial ischaemia.
6 The lack of relationship between PAI-1 concen-
tration and the number of circulating ‘early EPCs’ in the present
report is also consistent with ﬁndings in pre-clinical studies demon-
strating that PAI-1 alters the angiogenic response at the level of
ECs
36 and EPCs
6 migration. It should be also noted that the
inverse relationship between plasma PAI-1 concentration and cor-
onary collateral circulation, demonstrated in our study, could
partlyexplain the previously reported increased riskofcardiovascu-
lar events in subjects with a high concentration of PAI-1 in blood.
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Limitations
Our study was a single-centre study and patient referral and
medical management may have inﬂuenced the results. However,
it comprised a consecutive series of patients referred for a diagnos-
tic coronary angiography, and it is the largest study to date focusing
only on patients with coronary occlusion. In addition, careful
adjustment for the duration of coronary occlusion and other
potential risk factors strengthen our results. Analysis of coronary
collateral circulation by angiography because it is a semi-
quantitative method, requires a very strict methodology to
provide reliable results. To comply with that request, several
measures were taken: ﬁrst, a standardized method for performing
and recording angiography was used. Second, two complementary
and previously validated grading systems were used: one investi-
gating the size of collateral vessels (‘collateral ﬂow grade’) and
one the quality of the ﬁlling of the occluded vessel by the collate-
rals (‘recipient ﬁlling grade’). Third, the grading process was per-
formed by two independent observers and demonstrated a very
good inter-observer and overtime reproducibility. Internal consist-
ency among our results is also a guarantee for the quality of the
data: there was indeed a strong correlation between the results
Figure 2 Effect of the number of components of the metabolic
syndrome on the ‘collateral ﬂow grade’ (A; P ¼ 0.0005) and on
the number of circulating ‘early endothelial progenitor cells’ (B;
P ¼ 0.005).
MS and collateral vessel formation in patients with documented occluded coronary arteries 847of the two grading systems (R ¼ 0.76), whereas univariate and multi-
variable analyses identiﬁed similar correlates (data not shown).
Pressure- and Doppler-wire-derived measurements may also be
considered more physiologically relevant than angiographically
derived grading. However, previous studies have demonstrated a
good correlation between wire-derived and angiographic analyses
of collateral circulation.
38 In our study, the physiological relevance
of the angiographically derived grading is conﬁrmed by the obser-
vation that collateral circulation by angiography is highly associated
with LVEF. In addition, because the wire-derived techniques
require crossing the coronary occlusion with a device, they can
only be used in patients referred for a PCI of the occluded
vessel. In that regard, it is important to note that analyses restricted
to patients referred for a PCI of the occluded vessel in our popu-
lation demonstrated that this group was not representative of the
overall population in terms of duration of coronary occlusion,
severity of coronary artery disease, and LVEF (data not shown).
Analysis of the baseline patients’ characteristics of the largest
study performed with the use of wire-derived measurements con-
ﬁrmed this observation.
27 The use of angiography therefore
appears more suitable than wire-derived methods to investigate
collateral circulation in a large population with coronary occlusion
while avoiding major selection biases.
The present study did not ﬁnd a relationship between the use of
cardiovascularmedicationsandthedevelopmentofcoronarycollat-
erals.Toinvestigatethisissue,aspeciﬁcallydesignedstudyisneeded.
Although analysis of the relationship between MS and ‘early
EPCs’ provided interesting ﬁndings, it was performed in a small
subgroup and these exploratory results need conﬁrmation.
Conclusion
Our results demonstrate that patients with the MS and an occlusion
in a major epicardial coronary vessel have less developed coronary
collaterals than those without MS. This observation may explain the
well-documented higher risk of cardiac events in patients with the
MS.
2 It suggests that patients with the MS may constitute a parti-
cularly relevant group in which future investigation of pharmacolo-
gical, or other, strategies favouring the development of coronary
collaterals can be studied. Our results suggest also that novel bio-
logical mediators such as PAI-1 or adiponectin may be reasonable
targets to stimulate coronary collateral circulation.
Supplementary material
Supplementary material is available at European Heart Journal
Online.
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